Last reviewed · How we verify
Topical pomegranate seeds and peel extracts
Topical pomegranate seeds and peel extracts is a Small molecule drug developed by Cairo University. It is currently FDA-approved.
At a glance
| Generic name | Topical pomegranate seeds and peel extracts |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Topical pomegranate seeds and peel extracts CI brief — competitive landscape report
- Topical pomegranate seeds and peel extracts updates RSS · CI watch RSS
- Cairo University portfolio CI
Frequently asked questions about Topical pomegranate seeds and peel extracts
What is Topical pomegranate seeds and peel extracts?
Topical pomegranate seeds and peel extracts is a Small molecule drug developed by Cairo University.
Who makes Topical pomegranate seeds and peel extracts?
Topical pomegranate seeds and peel extracts is developed and marketed by Cairo University (see full Cairo University pipeline at /company/cairo-university).
What development phase is Topical pomegranate seeds and peel extracts in?
Topical pomegranate seeds and peel extracts is FDA-approved (marketed).